Cargando…
Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort
To evaluate the Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumour Association Prediction (DELTA-P) score in a prospective cohort of patients with newly diagnosed LEMS to assess the clinical validity of this tool in a real-world setting. Clinical features from 87 patients with LEMS, occur...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324357/ https://www.ncbi.nlm.nih.gov/pubmed/32601396 http://dx.doi.org/10.1038/s41598-020-67571-9 |
_version_ | 1783551923401523200 |
---|---|
author | Maddison, Paul Lipka, Alexander F. Gozzard, Paul Sadalage, Girija Ambrose, Philip A. Lang, Bethan Verschuuren, Jan J. |
author_facet | Maddison, Paul Lipka, Alexander F. Gozzard, Paul Sadalage, Girija Ambrose, Philip A. Lang, Bethan Verschuuren, Jan J. |
author_sort | Maddison, Paul |
collection | PubMed |
description | To evaluate the Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumour Association Prediction (DELTA-P) score in a prospective cohort of patients with newly diagnosed LEMS to assess the clinical validity of this tool in a real-world setting. Clinical features from 87 patients with LEMS, occurring within three months from disease onset, were collated to produce a DELTA-P score for each patient. Lung cancer was detected in 44/87 (51%) LEMS patients. Weight loss ≥ 5%, tobacco use at LEMS onset and age at onset ≥ 50 years were independent predictors for the development of small-cell lung cancer (SCLC) in LEMS patients in multivariable analysis. Median DELTA-P scores were significantly higher in SCLC-LEMS patients (3.5, 95% CI 3 to 4) compared to non-tumour-LEMS (2, 95% CI 1 to 2) (P < 0.0001). Higher DELTA-P scores increased the risk of SCLC stepwise (score 0 = 0%, 1 = 18.8%, 2 = 45%, 3 = 55.5%, 4 = 85.7%, 5 = 87.5%, 6 = 100%). The area under the curve of the receiver operating curve was 82.5% (95% CI 73.9% to 91%). The DELTA-P cancer prediction score, calculated at the time of LEMS diagnosis, is an effective tool for cancer screening in an independent, prospective study setting. |
format | Online Article Text |
id | pubmed-7324357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-73243572020-06-30 Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort Maddison, Paul Lipka, Alexander F. Gozzard, Paul Sadalage, Girija Ambrose, Philip A. Lang, Bethan Verschuuren, Jan J. Sci Rep Article To evaluate the Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumour Association Prediction (DELTA-P) score in a prospective cohort of patients with newly diagnosed LEMS to assess the clinical validity of this tool in a real-world setting. Clinical features from 87 patients with LEMS, occurring within three months from disease onset, were collated to produce a DELTA-P score for each patient. Lung cancer was detected in 44/87 (51%) LEMS patients. Weight loss ≥ 5%, tobacco use at LEMS onset and age at onset ≥ 50 years were independent predictors for the development of small-cell lung cancer (SCLC) in LEMS patients in multivariable analysis. Median DELTA-P scores were significantly higher in SCLC-LEMS patients (3.5, 95% CI 3 to 4) compared to non-tumour-LEMS (2, 95% CI 1 to 2) (P < 0.0001). Higher DELTA-P scores increased the risk of SCLC stepwise (score 0 = 0%, 1 = 18.8%, 2 = 45%, 3 = 55.5%, 4 = 85.7%, 5 = 87.5%, 6 = 100%). The area under the curve of the receiver operating curve was 82.5% (95% CI 73.9% to 91%). The DELTA-P cancer prediction score, calculated at the time of LEMS diagnosis, is an effective tool for cancer screening in an independent, prospective study setting. Nature Publishing Group UK 2020-06-29 /pmc/articles/PMC7324357/ /pubmed/32601396 http://dx.doi.org/10.1038/s41598-020-67571-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Maddison, Paul Lipka, Alexander F. Gozzard, Paul Sadalage, Girija Ambrose, Philip A. Lang, Bethan Verschuuren, Jan J. Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort |
title | Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort |
title_full | Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort |
title_fullStr | Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort |
title_full_unstemmed | Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort |
title_short | Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort |
title_sort | lung cancer prediction in lambert-eaton myasthenic syndrome in a prospective cohort |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324357/ https://www.ncbi.nlm.nih.gov/pubmed/32601396 http://dx.doi.org/10.1038/s41598-020-67571-9 |
work_keys_str_mv | AT maddisonpaul lungcancerpredictioninlamberteatonmyasthenicsyndromeinaprospectivecohort AT lipkaalexanderf lungcancerpredictioninlamberteatonmyasthenicsyndromeinaprospectivecohort AT gozzardpaul lungcancerpredictioninlamberteatonmyasthenicsyndromeinaprospectivecohort AT sadalagegirija lungcancerpredictioninlamberteatonmyasthenicsyndromeinaprospectivecohort AT ambrosephilipa lungcancerpredictioninlamberteatonmyasthenicsyndromeinaprospectivecohort AT langbethan lungcancerpredictioninlamberteatonmyasthenicsyndromeinaprospectivecohort AT verschuurenjanj lungcancerpredictioninlamberteatonmyasthenicsyndromeinaprospectivecohort |